EXEL

Exelixis is expected to report Q3 2026 earnings of $0.89 per share (up 14.1% YoY) and revenues of $653.06 million (up 9.3% YoY) on October 29. With a positive Earnings ESP of +2.44% and Zacks Rank #3, the company appears positioned to beat consensus estimates. Exelixis has beaten EPS estimates in all four trailing quarters.

The article recommends two underrated biotech stocks: Axsome Therapeutics, which is experiencing strong growth with its drug Auvelity (51% YoY sales growth) and has a promising pipeline including potential new indications; and Exelixis, a cancer-focused biotech with a dominant drug Cabometyx protected until at least 2030, plus encouraging progress on pipeline candidates like zanzalintinib.

Exelixis (EXEL), an oncology-focused biotechnology company, is highlighted as a stock to watch with a Zacks Rank #3 (Hold) and VGM Score of A. The company demonstrates strong growth potential with a Growth Style Score of A and forecasted year-over-year earnings growth of 15.9% for the current fiscal year, supported by recent upward analyst revisions.

Exelixis (EXEL), a biomedical and genetics drug developer, has demonstrated a consistent pattern of beating earnings estimates over the last two quarters with an average surprise of 10.91%. The company's positive Earnings ESP of +2.44% combined with its Zacks Rank #3 (Hold) rating suggests another potential earnings beat is likely, as stocks with this combination historically beat consensus estimates nearly 70% of the time.

Zacks Premium offers investment research tools including the Zacks Rank and Style Scores to help investors identify stocks with strong performance potential. The service combines value, growth, and momentum analysis to rate stocks, with historical data showing #1 Rank stocks averaging +23.8% annual returns since 1988. Exelixis (EXEL) is highlighted as a growth-focused biotech stock with a #3 Hold rating and Grade A VGM and Growth scores.

The bone metastasis in solid tumors market is expected to expand from 2026-2036 across seven major markets, driven by rising cancer survival rates, improved diagnostics, and growing demand for targeted therapies and radiopharmaceuticals. The market is characterized by established treatments like denosumab and zoledronic acid, with emerging therapies including cabozantinib and radioligand treatments. Key unmet needs include limited disease-modifying therapies, persistent skeletal complications, and lack of validated biomarkers for treatment selection.